Yamamura Kazuhiko, Nakahara Takeshi
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka 812-8582, Japan.
J Clin Med. 2022 Oct 18;11(20):6145. doi: 10.3390/jcm11206145.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, and the condition is typified by barrier dysfunction and immune dysregulation. Recent studies have characterized various phenotypes and endotypes of AD and elucidated the mechanism. Numerous topical and systemic narrow targeting therapies for AD have been developed according to these findings. Topical medications, including Janus kinase (JAK) inhibitors, phosphodiesterase 4 inhibitors, and the aryl hydrocarbon receptor agonist tapinarof, are effective and safe for AD compared to topical corticosteroids. Oral JAK inhibitors and monoclonal antibodies targeting interleukin (IL)-4, IL-13, IL-31, IL-33, OX40, thymic stromal lymphopoietin, and sphingosine 1-phosphate signaling have displayed outstanding efficacy against moderate-to-severe AD. We are currently in a new era of AD treatment.
特应性皮炎（AD）是最常见的慢性炎症性皮肤病之一，其特征为屏障功能障碍和免疫失调。最近的研究已对AD的各种表型和内型进行了特征描述并阐明了其机制。根据这些研究结果，已经开发出了多种用于AD的局部和全身窄谱靶向疗法。与局部用皮质类固醇相比，局部用药，包括 Janus激酶（JAK）抑制剂、磷酸二酯酶4抑制剂和芳烃受体激动剂他扎罗汀，对AD有效且安全。口服JAK抑制剂以及靶向白细胞介素（IL）-4、IL-13、IL-31、IL-33、OX40、胸腺基质淋巴细胞生成素和1-磷酸鞘氨醇信号传导的单克隆抗体，对中度至重度AD显示出卓越疗效。我们目前正处于AD治疗的新时代。
